Pancreatoduodenectomy after Roux-en-Y gastric bypass surgery: Single-center experience and literature review.

Scand J Surg

Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Oslo, NorwayInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.

Published: June 2023

Background And Objective: Bariatric surgery with Roux-en-Y gastric bypass (RYGB) is widely used to treat morbid obesity and present diagnostic and therapeutic challenges in patients with pancreatic and periampullary tumors. The aim of this study was to describe diagnostic tools and challenges in performing pancreatoduodenectomy (PD) on patients with altered anatomy after RYGB.

Methods: Patients undergoing PD after RYGB from April 2015 to June 2022 at a tertiary referral center were identified. Preoperative workup, operative techniques, and outcomes were reviewed. A literature search was performed to identify articles reporting PD in post-RYGB patients.

Results: Of a total of 788 PDs, six patients had previous RYGB. The majority were women (n = 5), and median age was 59 years. The patients most commonly presented with pain (50%) and jaundice (50%) with a median of 5.5 years after RYGB. The gastric remnant was resected in all cases, and reconstruction of the pancreatobiliary drainage was achieved using the distal part of the pre-existing pancreatobiliary limb in all patients. Median follow-up was 60 months. The Clavien-Dindo grade ⩾3 complications occurred in two patients (33.3%), and 90 days mortality occurred in one patient (16.6%). The literature search revealed 9 articles reporting a total of 122 cases, specifically addressing PD after RYGB.

Conclusions: Reconstruction after PD in post-RYGB patients may be challenging. Resection of the gastric remnant and use of the pre-existing biliopancreatic limb may be a safe strategy, but surgeons should be prepared for other reconstruction options for creation of a new pancreatobiliary limb.

Download full-text PDF

Source
http://dx.doi.org/10.1177/14574969231156350DOI Listing

Publication Analysis

Top Keywords

roux-en-y gastric
8
gastric bypass
8
patients
8
literature search
8
articles reporting
8
gastric remnant
8
pancreatobiliary limb
8
pancreatoduodenectomy roux-en-y
4
gastric
4
bypass surgery
4

Similar Publications

Outcomes and complications after long versus short gastric pouch Roux-en-Y gastric bypass in patients with severe obesity.

Sci Rep

December 2024

Department of Surgery, Minimally Invasive Surgery Research Center, Division of Minimally Invasive and Bariatric Surgery, Hazrat-E Fatemeh Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Roux-en-Y gastric bypass (RYGB) is the second most common metabolic and bariatric surgery (MBS) globally. The impact of pouch size on weight loss outcomes and complications remains unclear. This study aims to compare the weight loss outcomes and complications in long pouch versus short pouch RYGB in patients with severe obesity.

View Article and Find Full Text PDF

Background: Bariatric surgery is very effective in long-term weight management. The present study was undertaken to investigate the short-term effects of sleeve gastrectomy (SG) and of Roux-en-Y gastric bypass (RYGB) on (a) gastrointestinal (GI) motility, that is gastric emptying and oro-cecal transit time and (b) secretion of regulatory gut peptides and (c) their interrelationship.

Methods: Prospective single-centre study in which we assessed gastric emptying, oro-cecal transit time and gut peptide release in 28 severely obese individuals before and 2, respectively, 12 months after bariatric surgery (either SG or RYGB).

View Article and Find Full Text PDF

From the pioneering moment in 1987 when the insulinotropic effect of glucagon-like peptide 1 (GLP-1) was first demonstrated in humans, to today's pharmaceutical gold rush for GLP-1-based treatments of obesity, the journey of GLP-1 pharmacology has been nothing short of extraordinary. The sequential conceptual developments of long-acting GLP-1 receptor (GLP-1R) mono-agonists, GLP-1R/glucose-dependent insulinotropic polypeptide receptor (GIPR) dual-agonists, and GLP-1R/GIPR/glucagon receptor (GcgR) triple agonists, have led to profound body weight-lowering capacities, with benefits that extend past obesity and towards obesity-associated diseases. The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain types of bariatric surgery.

View Article and Find Full Text PDF

Unveiling the Masquerade: Early Gastric Cancer Mimicking Advanced Disease with Ectopic Pancreas Intrusion.

Ann Ital Chir

December 2024

Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy; General and Oncologic Surgery, Department of Surgery, Morgagni-Pierantoni Hospital, 47121 Forlì, Italy.

Gastric cancer is a significant health concern worldwide, and its diagnosis and management are of paramount importance. Ectopic pancreas (EP) refers to an embryological abnormality where healthy pancreatic tissue develops without anatomical, vascular, or neural communication with the normal pancreas. We report the case of a patient whose initial endoscopic evaluation suggested early gastric cancer, but computed tomography scan (CT scan) and endoscopic ultrasound (EUS) indicated a locally advanced tumor.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!